Halozyme Therapeutics (HTI) Misses Q4 EPS by 1c
Halozyme Therapeutics, Inc. (Amex: HTI) reports a Q4 loss of $0.07, 1 cent worse than estimates. Revenues were $426,000 vs. $210,000 consensus.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- Flowers Foods, Inc. (FLO) Reports In-Line Q1 EPS; Adjusts FY12 EPS Growth Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
